A bill for an act relating to the taxation and regulation of alternative nicotine products and vapor products, creating the Iowa cancer research fund, and including effective date provisions.(Formerly SF 475, SSB 1137.)
SF 638 would expand Iowa’s tobacco tax and regulatory framework to cover alternative nicotine products and vapor products more explicitly, including products containing nicotine analogs. The bill defines “nicotine analog,” broadens the statutory definitions of alternative nicotine products and vapor products, and updates multiple provisions in Iowa Code chapter 453A to apply licensing, recordkeeping, reporting, inspection, refund, and enforcement rules to these products in the same general manner as tobacco products.
The bill also creates a new excise tax of 10% of wholesale sales price on alternative nicotine products and vapor products, with a parallel 10% use-or-storage tax if the wholesale tax has not been paid. Revenues from this new tax are dedicated to a newly created Iowa cancer research fund administered under the authority of the Department of Health and Human Services. The fund is separate from the general fund, earns interest for the fund, cannot be disbursed before July 1, 2026, and may be used only for cancer research-related purposes through an application process developed by HHS.
The bill would amend numerous sections of Iowa Code chapter 453A to bring alternative nicotine products and vapor products under the same tax administration and compliance structure used for tobacco products. It would impose new licensing, reporting, inventory tax, refund, and enforcement obligations on distributors, subjobbers, retailers, consumers, and out-of-state sellers, while also authorizing the Department of Revenue to administer the new tax and related compliance provisions. It would further establish a dedicated, nonreverting Iowa cancer research fund and direct the new tax revenue to that fund rather than the general fund.
The available voting history suggests strong support for the bill in committee, with the Senate Ways and Means report passing 17-0. No committee transcript excerpts were provided, so there is no recorded floor or subcommittee debate in the supplied materials. Overall, the bill appears to have been treated as a revenue and public-health measure with broad committee approval.
The main policy issue implicit in the bill is the expansion of taxation and regulation to vaping and alternative nicotine products, including the treatment of nicotine analogs, which may affect manufacturers, distributors, retailers, and consumers of these products. Another likely point of discussion is the earmarking of the new tax revenue for cancer research rather than the general fund, which shifts the purpose of the tax from general revenue to a dedicated health-related fund. Because no transcript was provided, there is no documented opposition in the supplied record, but the bill’s reach into emerging nicotine products and its new tax burden are the most likely areas of contention.